Chromone derivatives as matrix metalloproteinase inhibitors

Details Chromone derivatives as matrix metalloproteinase inhibitors Chromone derivatives as matrix metalloproteinase inhibitors

C - Chemistry, Metallurgy

07

D

C07D 311/22 (2006.01) A61K 31/352 (2006.01) A61K 31/536 (2006.01) A61P 29/00 (2006.01) C07D 265/22 (2006.01)

Patent

CA 2497658

This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof, wherein R1, Q, y2, y3, Y4, U5, U6, U8, and R2 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically 10 acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MW-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MNIP 13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.

L'invention concerne des composés, ou des sels de ces composés acceptables sur le plan pharmaceutique, définis par la formule (I), dans laquelle R?1¿, Q, Y?1¿, Y?3¿, Y?5¿, Y?6¿, Y?8¿, et R?2¿ sont définis dans la description. Elle concerne aussi des compositions pharmaceutiques contenant un composé de formule (1), ou un sel de ce composé acceptable sur le plan pharmaceutique, tel que défini dans la description avec un support, diluent ou excipient, acceptable sur le plan pharmaceutique. Elle concerne encore des procédés d'inhibition d'une enzyme MMP-13 chez l'animal consistant à administrer à l'animal un composé de formule (1), ou un sel de ce composé acceptable sur le plan pharmaceutique, ainsi que des procédés d'inhibition d'une enzyme MMP-13 chez l'homme consistant à administrer à l'animal un composé de formule (1), ou un sel de ce composé acceptable sur le plan pharmaceutique, soit seul ou dans une composition pharmaceutique. L'invention concerne aussi des méthodes de traitement de maladies notamment cardio-vasculaire, sclérose multiple, ostéo-arthrite et arthrite rhumatoïde, arthrites autres qu'ostéo-arthrite et arthrite rhumatoïde, insuffisance cardiaque, inflammation de l'intestin, crise cardiaque, dégénérescence due à l'âge, broncho-pneumopathie chronique obstructive, asthme, parodontite, psoriasis, athérosclérose et ostéoporose chez un patient consistant à administrer au patient un composé de formule (I), ou un sel de ce composé acceptable sur le plan pharmaceutique, soit seul ou dans une composition pharmaceutique. L'invention concerne enfin des combinaisons comprenant un composé de formule (I), ou un sel de ce composé acceptable sur le plan pharmaceutique, et un autre principe actif pharmaceutique tel que décrit.

Affiliated with

Also associated with

Rating

Chromone derivatives as matrix metalloproteinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chromone derivatives as matrix metalloproteinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chromone derivatives as matrix metalloproteinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1920862